CORT
Corcept Therapeutics Inc. Healthcare - Biotechnology Investor Relations →
Corcept Therapeutics Inc. (CORT) closed at $34.64 as of 2026-03-20, trading 14.1% below its 200-week moving average of $40.32. This places CORT in the extreme value zone. The stock moved further from the line this week, up from -20.1% last week. With a 14-week RSI of 17, CORT is in oversold territory.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.96 ratio) is neutral — neither side is clearly dominating.
Over the past 1096 weeks of data, CORT has crossed below its 200-week moving average 18 times. On average, these episodes lasted 21 weeks. Historically, investors who bought CORT at the start of these episodes saw an average one-year return of +70.2%.
With a market cap of $3.7 billion, CORT is a mid-cap stock. The company generates a free cash flow yield of 3.1%. Return on equity stands at 15.0%, a solid level. The stock trades at 5.7x book value.
CORT passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 21.1 years, a hypothetical investment of $100 in CORT would have grown to $806, compared to $813 for the S&P 500. CORT has returned 10.4% annualized vs 10.4% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 1 open-market purchase totaling $3,313,809. Notably, these purchases occurred while CORT is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been growing at a 5.7% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CORT vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CORT Crosses Below the Line?
Across 17 historical episodes, buying CORT when it crossed below its 200-week moving average produced an average return of +67.2% after 12 months (median +55.0%), compared to +16.0% for the S&P 500 over the same periods. 81% of those episodes were profitable after one year. After 24 months, the average return was +73.3% vs +32.7% for the index.
Each line shows $100 invested at the moment CORT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CORT has crossed below its 200-week MA 18 times with an average 1-year return of +70.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2005 | Sep 2007 | 130 | 87.0% | +14.2% | +668.1% |
| Oct 2007 | Nov 2009 | 108 | 73.1% | -76.1% | +728.7% |
| Nov 2009 | Nov 2009 | 2 | 7.1% | +70.9% | +1581.6% |
| Sep 2012 | Dec 2013 | 67 | 55.4% | -34.5% | +1197.4% |
| Jan 2014 | Jan 2014 | 1 | 0.1% | -4.9% | +1039.5% |
| May 2014 | Oct 2014 | 24 | 40.0% | +198.9% | +1782.6% |
| Jan 2015 | Jan 2015 | 1 | 0.2% | +32.2% | +1098.6% |
| Jan 2019 | Feb 2019 | 1 | 3.3% | +26.3% | +245.4% |
| May 2019 | Jul 2019 | 9 | 9.9% | +52.8% | +236.0% |
| Dec 2019 | Jan 2020 | 1 | 0.1% | +115.7% | +185.6% |
| Mar 2020 | May 2020 | 9 | 18.3% | +112.4% | +199.7% |
| Aug 2020 | Aug 2020 | 2 | 6.7% | +59.4% | +168.1% |
| Feb 2023 | Mar 2023 | 1 | 1.0% | +25.3% | +80.4% |
| Jan 2024 | Feb 2024 | 2 | 4.4% | +177.0% | +59.9% |
| Feb 2024 | Feb 2024 | 1 | 1.2% | +183.0% | +54.3% |
| Apr 2024 | Apr 2024 | 2 | 1.5% | +171.2% | +50.9% |
| Dec 2025 | Jan 2026 | 3 | 12.4% | N/A | -9.3% |
| Feb 2026 | Ongoing | 6+ | 20.1% | Ongoing | -13.3% |
| Average | 21 | — | +70.2% | — |
Frequently Asked Questions
Is CORT below its 200-week moving average?
Yes. As of 2026-03-20, Corcept Therapeutics Inc. (CORT) is trading 14.1% below its 200-week moving average of $40.32. The current price is $34.64.
What is CORT's 200-week moving average price?
Corcept Therapeutics Inc.'s 200-week moving average is $40.32 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CORT drops below its 200-week moving average?
CORT has crossed below its 200-week moving average 18 times in our data. On average, buying at that moment produced a one-year return of +70.2%. These dips have historically been decent entry points. These episodes lasted 21 weeks on average.
Is CORT a good value right now?
Here's what our data says about CORT as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 17 (oversold). Free cash flow yield is 3.1%. Return on equity is 15.0%. Price-to-book is 5.7x. This is not a buy or sell recommendation — always do your own research.
How does CORT compare to the S&P 500?
Over the past 21.1 years, $100 invested in CORT would have grown to $806, compared to $813 for the S&P 500. That's 10.4% annualized vs 10.4% for the index. CORT has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20